ASSAIL-MI trial studied 200 pt with new (<6hr) STEMI-randomized to either PBO or IV 280 mg tocilizumab. While no signif difference in final infarct size (7.2 vs 9.1%; P=.08), TCZ treated pts had better myocardial salvage & less Microvascular obstruction https://t.co/WRRGXCbP5O